Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 2/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.38 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.36 |
| ▸ | SLC34A1 | Q06495 | 4/20 | 0.35 |
| ▸ | ABL1 | P00519 | 5/20 | 0.35 |
| ▸ | BCR | P11274 | 5/20 | 0.35 |
| ▸ | GCG | P01275 | 1/20 | 0.34 |
| ▸ | GCGR | P47871 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16983155 | 0.86 | NOTUM (0.39) | RXRAGRIN1GRIN2BCYP46A1SLC34A1 | |
| SCHEMBL12470367 | 0.79 | MBOAT4 (0.40) | RXRAGRIN1GRIN2BCYP46A1SLC34A1 | |
| SCHEMBL28851926 | 0.79 | EPHX2 (0.39) | RXRAGRIN1GRIN2BCYP46A1SLC34A1 | |
| SCHEMBL17666300 | 0.77 | GCG (0.40) | CYP46A1ABL1BCRGCGGCGR | |
| SCHEMBL17666294 | 0.75 | PDE10A (0.32) | PDE10AMBOAT4 | |
| SCHEMBL18456208 | 0.75 | RXRA (0.41) | RXRAGRIN1GRIN2BNOTUM | |
| SCHEMBL16983105 | 0.75 | GCG (0.39) | RXRAGRIN1GRIN2BCYP46A1ABL1 | |
| SCHEMBL11900303 | 0.75 | EPHX2 (0.44) | CYP46A1ABL1BCRGCGGCGR | |
| SCHEMBL17666293 | 0.74 | MELK (0.36) | RIPK2 | |
| SCHEMBL11899948 | 0.73 | GCG (0.46) | RXRAGRIN1GRIN2BGCGGCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170002006-A1 | MACROCYCLES WITH HETROCYCLIC P2' GROUPS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-01-05 | — | — | US | disclosed |
| US-9453018-B2 | Pyrimidinones as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-09-27 | — | — | US | disclosed |
| US-20160096839-A1 | PYRIMIDINONES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2016-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170002006-A1 | MACROCYCLES WITH HETROCYCLIC P2' GROUPS AS FACTOR XIA INHIBITORS | TFPI2, F2, TFPI | RXRA 4364/4885GRIN1 4461/4885GRIN2B 3998/4885 |
| US-20160096839-A1 | PYRIMIDINONES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F2 | RXRA 4646/4885GRIN1 2872/4885GRIN2B 2964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.